Substance / Medication

Lisocabtagene maraleucel

Overview

Active Ingredient
lisocabtagene maraleucel
RxNorm CUI
2479136

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
FDA Approval Summary: Lisocabtagene Maraleucel for Second-Line Treatment of Large B-Cell Lymphoma.
Elmacken Mona, Peredo-Pinto Helkha, Wang Cong et al. · Clin Cancer Res · 2024
PMID: 38324398RCT
Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL.
Abramson Jeremy S, Johnston Patrick B, Kamdar Manali et al. · Blood Adv · 2022
PMID: 36149968RCTFull text (PMC)
A real-world comparison of commercial-use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphoma.
Looka Andrew, Qualls David A, Matthews Daniel et al. · Blood Adv · 2025
PMID: 39546746ObservationalFull text (PMC)
Lisocabtagene maraleucel for relapsed/refractory large B-cell lymphoma: a cell therapy consortium real-world analysis.
Riedell Peter A, Grady Connor B, Nastoupil Loretta J et al. · Blood Adv · 2025
PMID: 39657136ObservationalFull text (PMC)
FDA Approval Summary: Lisocabtagene Maraleucel for Relapsed or Refractory Follicular Lymphoma.
Britton Kristen, Mahat Upendra, Richardson Nicholas C et al. · Clin Cancer Res · 2025
PMID: 40663365ObservationalFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Lisocabtagene maraleucel (substance)
SNOMED CT
1148744000
UMLS CUI
C4086001
RxNorm CUI
2479136

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.